Photocure - meet the management event, June 29th 2021
Photocure develops and commercialises solutions for better detection and management of bladder cancer. The company showed strong revenue growth in Q1 after having regained the commercial rights for Hexvix in European countries, in addition to a growth in the installed base in the US. The use of the Photocure-technology, where the drug makes cancer cells glow bright pink, has led to better bladder cancer patient management globally and the company sees significant long-term potential in the global bladder cancer market. Photocure is listed on the Oslo Stock Exchange with a current market value of NOK 3,8 billion.
CEO Daniel Schneider, Susanne Strauss, General Manager for Europe, Geoffrey Coy, General Manager for the U.S. and Investor Relation Officer David Moskowitz will participate in a live Q&A event via Xtrainvestor and inQrate on Tuesday 29/6 at 15:00 CET to talk about the development in Europe and in the US. In addition, this is an opportunity to meet the management team before the summer.
Send in your questions to email@example.com